Karyopharm Therapeutics Inc (KPTI)

NASDAQ
4.24
-0.16(-3.64%)
After Hours
4.24
0.00(0.00%)
- Real-time Data
  • Volume:
    1,032,054
  • Day's Range:
    4.23 - 4.57
  • 52 wk Range:
    4.00 - 14.73

KPTI Overview

Prev. Close
4.4
Day's Range
4.23-4.57
Revenue
234.23M
Open
4.34
52 wk Range
4-14.73
EPS
-1.34
Volume
1,032,054
Market Cap
338.38M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
1,882,105
P/E Ratio
-4.28
Beta
0.008
1-Year Change
-32.27%
Shares Outstanding
79,806,616
Next Earnings Date
Nov 07, 2022
What is your sentiment on Karyopharm?
or
Market is currently closed. Voting is open during market hours.

Karyopharm Therapeutics Inc News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade

Karyopharm Therapeutics Inc Analysis

Karyopharm Therapeutics Inc Company Profile

Karyopharm Therapeutics Inc Company Profile

Employees
442

Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company. The Company is focused on the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. Its Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (CRM1). Its lead compound, XPOVIO (selinexor), is marketed in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). NEXPOVIO (selinexor), the brand name for XPOVIO in Europe and the United Kingdom, in combination with dexamethasone to treat adult patients with multiple myeloma.

Read More

Analyst Price Target

Average12.38 (+191.86% Upside)
High21
Low5
Price4.24
No. of Analysts8
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Analysts 12-Month Price Target

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellStrong SellStrong Sell
Technical IndicatorsStrong SellStrong SellStrong SellStrong SellStrong Sell
SummaryStrong SellStrong SellStrong SellStrong SellStrong Sell
  • nobody here no comments ?
    0
    • yeah nobody.!
      0
  • Should reach USD 25 fairvalue by Mar
    2
    • eanings 🚀🚀🚀
      0
      • REVENUE BEAT 33.51M OVER EST 28.41M, undervalued based on upgrades - reported by Reuters June 23: H.C. Wainwright raises target price to $41 from $40, Jefferies raises target price to $35 from $34, JP Morgan raises target price to $37 from $31, RBC raises target price to $30 from $28, SVB Leerink raises target price to $31 from $29
        0
        • bullish
          0
          • KPTI. We like this stock and see it doubling from here in back half of 2020. Last: $18.99.
            1
            • What is the target?
              0
              • 20.00 It just rose 70 % ! In one Day alone.... I expect a Big Discount. They knew what they were up too! That's why they drove the price up so astronomically for the OFFERING! Happens all the time...and we get the Shaft!
                0
              • is it good to buy today?
                0